Thromb Haemost 2020; 120(02): 216-228
DOI: 10.1055/s-0039-3401822
Coagulation and Fibrinolysis
Georg Thieme Verlag KG Stuttgart · New York

Cost-Effectiveness and Budget Impact of Emicizumab Prophylaxis in Haemophilia A Patients with Inhibitors

Paolo Angelo Cortesi
1   Research Centre on Public Health (CESP), University of Milano-Bicocca, Monza, Italy
Giancarlo Castaman
2   Center for Bleeding Disorders and Coagulation, Careggi University Hospital, Florence, Italy
Gianluca Trifirò
3   Department of Biomedical and Dental Sciences and Morpho-functional Imaging, University of Messina, Messina, Italy
Simona Serao Creazzola
4   UOC Farmaceutica Convenzionata e Territoriale, ASL Napoli 1 Centro, Naples, Italy
Giovanni Improta
5   Department of Public Health, University of Naples “Federico II,” Naples, Italy
Giampiero Mazzaglia
1   Research Centre on Public Health (CESP), University of Milano-Bicocca, Monza, Italy
Angelo Claudio Molinari
6   Regional Reference Center for Hemorrhagic Diseases, Giannina Gaslini Institute, Genova, Italy
Lorenzo Giovanni Mantovani
1   Research Centre on Public Health (CESP), University of Milano-Bicocca, Monza, Italy
› Author Affiliations
Funding This analysis was funded by an unrestricted grant of Roche Italy spa.
Further Information

Publication History

28 May 2019

22 October 2019

Publication Date:
30 December 2019 (online)


Recent evidence demonstrated that weekly prophylaxis with subcutaneous bispecific antibody (emicizumab) has shown higher efficacy in adolescent and adults patients affected by haemophilia A (HA) with inhibitor, compared with patients treated on demand or on prophylaxis with bypassing agents (BPAs). However, no economic evaluations assessing the value and sustainability of emicizumab prophylaxis have been performed in Europe. This study assessed the cost-effectiveness of emicizumab prophylaxis compared with BPA prophylaxis and its possible budget impact from the Italian National Health Service (NHS) perspective. A Markov model and a budget impact model were developed to estimate the cost-effectiveness and budget impact of emicizumab prophylaxis in HA patients with inhibitors. The model was populated using treatment efficacy from clinical trials and key clinical, cost and epidemiological data retrieved through an extensive literature review. Compared with BPAs prophylaxis, emicizumab prophylaxis was found to be more effective (0.94 quality adjusted life-years) and cost saving (–€19.4/–€24.4 million per patient lifetime) in a cohort of 4-year-old patients with HA and inhibitors who failed immune tolerance induction. In the probabilistic sensitivity analysis, emicizumab prophylaxis had always 100% probability of being cost-effective at any threshold. Further, the use of emicizumab prophylaxis was associated to an overall budget reduction of €45.4 million in the next 3 years. In conclusion, the clinically effective emicizumab prophylaxis can be considered a cost-saving treatment for HA with inhibitor patients. Furthermore, emicizumab treatment is also associated to a significant reduction of the health care budget, making this new treatment a sustainable and convenient health care option for Italian NHS.


No Roche employees had sight of, contributed to or commented upon the manuscript draft ahead of submission. All authors contributed to the concept and objectives of the analysis.

Authors' Contributions

P.A.C. designed and developed the economic model and ran the analyses. The economic implications of the results were interpreted by P.A.C., G.T., S.C.S., I.G., M.G. and L.G.M., while the implications for clinical practice were interpreted by A.C.M. and G.C. The draft manuscript was prepared by P.A.C. and was reviewed, edited and approved by all authors.

Supplementary Material

  • References

  • 1 White II GC, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J. ; Factor VIII and Factor IX Subcommittee. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 2001; 85 (03) 560
  • 2 Escobar M, Sallah S. Hemophilia A and hemophilia B: focus on arthropathy and variables affecting bleeding severity and prophylaxis. J Thromb Haemost 2013; 11 (08) 1449-1453
  • 3 Kreuz W, Ettingshausen CE. Inhibitors in patients with haemophilia A. Thromb Res 2014; 134 (Suppl. 01) S22-S26
  • 4 Carcao MD. The diagnosis and management of congenital hemophilia. Semin Thromb Hemost 2012; 38 (07) 727-734
  • 5 Witmer C, Presley R, Kulkarni R, Soucie JM, Manno CS, Raffini L. Associations between intracranial haemorrhage and prescribed prophylaxis in a large cohort of haemophilia patients in the United States. Br J Haematol 2011; 152 (02) 211-216
  • 6 Rota M, Cortesi PA, Steinitz-Trost KN, Reininger AJ, Gringeri A, Mantovani LG. Meta-analysis on incidence of inhibitors in patients with haemophilia A treated with recombinant factor VIII products. Blood Coagul Fibrinolysis 2017; 28 (08) 627-637
  • 7 Gouw SC, van der Bom JG, Auerswald G, Ettinghausen CE, Tedgård U, van den Berg HM. Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study. Blood 2007; 109 (11) 4693-4697
  • 8 Gringeri A, Mantovani LG, Scalone L, Mannucci PM. ; COCIS Study Group. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood 2003; 102 (07) 2358-2363
  • 9 Scalone L, Mantovani LG, Mannucci PM, Gringeri A. ; COCIS Study Investigators. Quality of life is associated to the orthopaedic status in haemophilic patients with inhibitors. Haemophilia 2006; 12 (02) 154-162
  • 10 Rocino A, Franchini M, Coppola A. Treatment and prevention of bleeds in haemophilia patients with inhibitors to factor VIII/IX. J Clin Med 2017; 6 (04) E46
  • 11 Rocino A, Cortesi PA, Scalone L, Mantovani LG, Crea R, Gringeri A. ; European Haemophilia Therapy Strategy Board (EHTSB); European Haemophilia Therapy Strategy Board EHTSB. Immune tolerance induction in patients with haemophilia a and inhibitors: effectiveness and cost analysis in an European Cohort (The ITER Study). Haemophilia 2016; 22 (01) 96-102
  • 12 Colowick AB, Bohn RL, Avorn J, Ewenstein BM. Immune tolerance induction in hemophilia patients with inhibitors: costly can be cheaper. Blood 2000; 96 (05) 1698-1702
  • 13 Earnshaw SR, Graham CN, McDade CL, Spears JB, Kessler CM. Factor VIII alloantibody inhibitors: cost analysis of immune tolerance induction vs. prophylaxis and on-demand with bypass treatment. Haemophilia 2015; 21 (03) 310-319
  • 14 Konkle BA, Ebbesen LS, Erhardtsen E. , et al. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost 2007; 5 (09) 1904-1913
  • 15 Leissinger C, Gringeri A, Antmen B. , et al. Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors. N Engl J Med 2011; 365 (18) 1684-1692
  • 16 Antunes SV, Tangada S, Stasyshyn O. , et al. Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors. Haemophilia 2014; 20 (01) 65-72
  • 17 Mahlangu J, Oldenburg J, Callaghan MU. , et al. Bleeding events and safety outcomes in persons with haemophilia A with inhibitors: a prospective, multi-centre, non-interventional study. Haemophilia 2018; 24 (06) 921-929
  • 18 Astermark J, Donfield SM, DiMichele DM. , et al; FENOC Study Group. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood 2007; 109 (02) 546-551
  • 19 Oldenburg J, Mahlangu JN, Kim B. , et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med 2017; 377 (09) 809-818
  • 20 Shima M, Hanabusa H, Taki M. , et al. Long-term safety and efficacy of emicizumab in a phase 1/2 study in patients with hemophilia A with or without inhibitors. Blood Adv 2017; 1 (22) 1891-1899
  • 21 Oldenburg J, Mahlangu JN, Bujan W. , et al. The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study. Haemophilia 2019; 25 (01) 33-44
  • 22 Young G, Sidonio RF, Liesner R. , et al. HAVEN 2 updated analysis: multicenter, open-label, phase 3 study to evaluate efficacy, safety and pharmacokinetics of subcutaneous administration of emicizumab prophylaxis in pediatric patients with hemophilia A with inhibitors. Blood 2017; 130: 85
  • 23 Roberts M, Russell LB, Paltiel AD, Chambers M, McEwan P, Krahn M. ; ISPOR-SMDM Modeling Good Research Practices Task Force. Conceptualizing a model: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--2. Value Health 2012; 15 (06) 804-811
  • 24 Siebert U, Alagoz O, Bayoumi AM. , et al; ISPOR-SMDM Modeling Good Research Practices Task Force. State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--3. Value Health 2012; 15 (06) 812-820
  • 25 Farrugia A, Cassar J, Kimber MC. , et al. Treatment for life for severe haemophilia A- A cost-utility model for prophylaxis vs. on-demand treatment. Haemophilia 2013; 19 (04) e228-e238
  • 26 Knight C, Paisley S, Wight J, Jones ML. Economic modelling of different treatment strategies for haemophilia A with high-responding inhibitors. Haemophilia 2003; 9 (04) 521-540
  • 27 Machin N, Ragni MV, Smith KJ. Gene therapy in hemophilia A: a cost-effectiveness analysis. Blood Adv 2018; 2 (14) 1792-1798
  • 28 D'Angiolella LS, Cortesi PA, Rocino A. , et al. The socioeconomic burden of patients affected by hemophilia with inhibitors. Eur J Haematol 2018; 101 (04) 435-456
  • 29 Coppola A, Franchini M, Castaman G. , et al; AICE ad hoc Working Group. Treatment regimens with bypassing agents in patients with hemophilia A and inhibitors: a survey from the Italian Association of Hemophilia Centers (AICE). Semin Thromb Hemost 2018; 44 (06) 551-560
  • 30 Abbonizio F, Giampaolo A, Riccioni R. , et al.; Associazione Italiana Centri Emofilia (AICE). Registro Nazionale Coagulopatie Congenite. Rapporto 2016. Roma: Istituto Superiore di Sanità; 2018 . (Rapporti ISTISAN 18/1). Available at: . Accessed April 16, 2019
  • 31 Collins PW, Chalmers E, Hart DP. , et al; UK Haemophilia Centre Doctors. Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: 4th ed. Br J Haematol 2013; 160 (02) 153-170
  • 32 Giangrande PLF, Hermans C, O'Mahony B. , et al; European Haemophilia Consortium (EHC) and the European Association for Haemophilia and Allied Disorders (EAHAD). European principles of inhibitor management in patients with haemophilia. Orphanet J Rare Dis 2018; 13 (01) 66
  • 33 Cortesi PA, Belli LS, Facchetti R. , et al; European Liver and Intestine Transplant Association (ELITA). The optimal timing of hepatitis C therapy in liver transplant-eligible patients: cost-effectiveness analysis of new opportunities. J Viral Hepat 2018; 25 (07) 791-801
  • 34 Darby SC, Kan SW, Spooner RJ. , et al. Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV. Blood 2007; 110 (03) 815-825
  • 35 ISTAT– Italian National Institute of Statistics. Mortality Table 2017. Available at: . Accessed January 29, 2019
  • 36 Cortesi PA, D'Angiolella LS, Lafranconi A, Micale M, Cesana G, Mantovani LG. Modern treatments of haemophilia: review of cost-effectiveness analyses and future directions. Pharmacoeconomics 2018; 36 (03) 263-284
  • 37 Gringeri A, Leissinger C, Cortesi PA. , et al. Health-related quality of life in patients with haemophilia and inhibitors on prophylaxis with anti-inhibitor complex concentrate: results from the Pro-FEIBA study. Haemophilia 2013; 19 (05) 736-743
  • 38 FAO – Food and Agriculture Organization of the United Nations. Body weights and heights by countries. Available at: . Accessed April 16, 2019
  • 39 WHO – World Health Organization. Child growth standards. Weight-for-age tables, Boys percentiles. Available at: . Accessed April 16, 2019
  • 40 Santagostino E, Escobar M, Ozelo M. , et al. Recombinant activated factor VII in the treatment of bleeds and for the prevention of surgery-related bleeding in congenital haemophilia with inhibitors. Blood Rev 2015; 29 (Suppl. 01) S9-S18
  • 41 Srivastava A, Brewer AK, Mauser-Bunschoten EP. , et al; Treatment Guidelines Working Group on Behalf of The World Federation Of Hemophilia. Guidelines for the management of hemophilia. Haemophilia 2013; 19 (01) e1-e47
  • 42 Gazzetta Ufficiale della Repubblica Italiana. 28 January 2013. Remunerazione delle prestazioni di assistenza ospedaliera per acuti, assistenza ospedaliera di riabilitazione e di lungodegenza post acuzie e di assistenza specialistica ambulatoriale. Available at: . Accessed April 16, 2019
  • 43 AIFA – Agenzia Italiana del Farmaco. Available at: . Accessed April 16, 2019
  • 44 Mahlangu J, Powell JS, Ragni MV. , et al; A-LONG Investigators. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood 2014; 123 (03) 317-325
  • 45 Tiede A, Oldenburg J, Lissitchkov T, Knaub S, Bichler J, Manco-Johnson MJ. Prophylaxis vs. on-demand treatment with Nuwiq(®) (Human-cl rhFVIII) in adults with severe haemophilia A. Haemophilia 2016; 22 (03) 374-380
  • 46 Tagariello G, Iorio A, Santagostino E. , et al; Italian Association Hemophilia Centre (AICE). Comparison of the rates of joint arthroplasty in patients with severe factor VIII and IX deficiency: an index of different clinical severity of the 2 coagulation disorders. Blood 2009; 114 (04) 779-784
  • 47 Colombo GL, Di Matteo S, Mancuso ME, Santagostino E. Cost-utility analysis of prophylaxis versus treatment on demand in severe hemophilia A. Clinicoecon Outcomes Res 2011; 3: 55-61
  • 48 Rangarajan S, Austin S, Goddard NJ. , et al. Consensus recommendations for the use of FEIBA(®) in haemophilia A patients with inhibitors undergoing elective orthopaedic and non-orthopaedic surgery. Haemophilia 2013; 19 (02) 294-303
  • 49 ISTAT– Italian National Institute of Statistics. Consumer Price Index table, 2018. Available at: . Accessed January 29, 2019
  • 50 Tagliaferri A, Franchini M, Coppola A. , et al. Effects of secondary prophylaxis started in adolescent and adult haemophiliacs. Haemophilia 2008; 14 (05) 945-951
  • 51 Ollendorf DA, Chapman RH, Pearson SD. Evaluating and valuing drugs for rare conditions: no easy answers. Value Health 2018; 21 (05) 547-552
  • 52 ICER – Institute for Clinical and Economic Review. Emicizumab for hemophilia A with inhibitors: effectiveness and value. Final evidence report. April 16, 2018. Available at: . Accessed April 16, 2019
  • 53 Blanchette VS, Key NS, Ljung LR, Manco-Johnson MJ, van den Berg HM, Srivastava A. ; Subcommittee on Factor VIII, Factor IX and Rare Coagulation Disorders of the Scientific and Standardization Committee of the International Society on Thrombosis and Hemostasis. Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost 2014; 12 (11) 1935-1939
  • 54 Nugent D, Kalnins W, Querol F. , et al. Haemophilia Experiences, Results and Opportunities (HERO) study: treatment-related characteristics of the population. Haemophilia 2015; 21 (01) e26-e38
  • 55 Mahlangu J, Oldenburg J, Paz-Priel I. , et al. Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N Engl J Med 2018; 379 (09) 811-822
  • 56 Perrin GQ, Herzog RW, Markusic DM. Update on clinical gene therapy for hemophilia. Blood 2019; 133 (05) 407-414
  • 57 Weyand AC, Pipe SW. New therapies for hemophilia. Blood 2019; 133 (05) 389-398